Company: DHR
Filing Date: 2025-10-21
Form Type: 10-Q
Source: 0000313616-25-000182
Chunk: 153

Company: DANAHER CORP /DE/
Filing Date: 2025-10-21
Form: 10-Q
Item: Item 2
Chunk 153
---
$1,653 $5,260 $4,890 Operating profit352 390 1,324 1,177 Depreciation38 36 110 113 Amortization of intangible assets231 218 672 650 Operating profit as a % of sales19.6 %23.6 %25.2 %24.1 %Depreciation as a % of sales2.1 %2.2 %2.1 %2.3 %Amortization as a % of sales12.8 %13.2 %12.8 %13.3 %

Sales Growth and Core Sales Growth% Change Three-Month Period Ended September 26, 2025 vs. Comparable 2024 Period% Change Nine-Month Period Ended September 26, 2025 vs. Comparable 2024 PeriodTotal sales growth (GAAP)9.0 %7.5 %Impact of:Currency exchange rates (2.5)%(1.0)%Core sales growth (non-GAAP)6.5 %6.5 %

Price increases in the segment contributed 2.5% and 2.0%, respectively, to sales growth on a year-over-year basis during the three and nine-month periods ended September 26, 2025 and are reflected as a component of core sales above.

Total segment sales increased 9.0% and 7.5% during the three and nine-month periods, respectively.  The increase in segment sales in the three and nine-month periods was led by increased core sales and to a lesser extent by the impact of currency exchange rates.  The year-over-year increase in total segment core sales in both periods was led by increased sales of consumables, partially offset by declines in equipment sales.  Geographically, the increase in core sales was led by North America in the three-month period and North America and Western Europe in the nine-month period.  Based on the current market conditions, the Company expects a cautious equipment spending environment through the remainder of the year.

The year-over-year increase in core sales in the segment was led by high-single digit increases in core sales in the bioprocessing business in both the three and nine-month periods and was primarily driven by improved consumables demand from large pharmaceutical customers, partially offset by lower year-over-year demand for equipment.  Core sales in the discovery and medical business increased year-over-year as demand for medical and lab